This Article  • PDF of this Correction  • Original article  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

Arch Neurol. 2000;57:1741.

In the Original Contribution by Traynor et al titled "Clinical Features of Amyotrophic Lateral Sclerosis According to the El Escorial and Airlie House Diagnostic Criteria: A Population-Based Study," published in the August issue of the ARCHIVES (2000;57:1171-1176), 4 errors occurred in the second paragraph on page 1175. The words primary lateral sclerosis should have read progressive muscular atrophy in the 10th, 20th, 21st, and 28th lines of this paragraph. The paragraph should have read as follows: "Currently, patients with ALS who have only LMN signs are excluded from clinical trials, and the suspected category has been deleted from the revised EEC.ing:reference out-of-sequence² Our study demonstrates that patients with suspected ALS at diagnosis have a clinically similar course to patients in the other ALS categories: survival of the 29 patients with suspected ALS at diagnosis was statistically similar to patient survival in other EEC or AHC categories (Figure 1). As only 3 of the 254 deceased Irish patients with ALS had clinical features of progressive muscular atrophy at the time of death, it is apparent that the majority of patients with only LMN signs at an early stage ultimately progress to other categories. Two of these cases proceeded to autopsy, of which one was an autopsy-proved case in a 74-year-old woman. The other was in a 54-year-old man without clinical UMN signs before death, but postmortem examination disclosed corticospinal involvement. The postmortem finding of ubiquinated neuronal inclusions, the pathological hallmark of ALS,²³ in several cases of progressive muscular atrophy strengthens the view that the clinical diagnosis of progressive muscular atrophy represents ALS.¹⁸ Furthermore, patients with superoxide dismutase 1 mutations are known to initially manifest solely LMN findings¹⁶ and are included as having clinically definite familial, laboratory-supported ALS.²⁴ Until the underlying pathogenic mechanisms of ALS are more fully understood, we believe that current evidence supports the inclusion of progessive muscular atrophy and suspected ALS that is clearly progressing in clinical trials."